Search research articles
Contact Us
Filters
Showing results (151-160 of 257) with videos related to
Page
of 26
Sort By:
Blood
|
February 27, 2026
Isatuximab, bortezomib, lenalidomide, dexamethasone for multiple myeloma: dynamics of MRD-negativity in the IMROZ study
Robert Z Orlowski, Meletios A Dimopoulos, Xavier Leleu, et al.
Haematologica
|
May 10, 2007
Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC)
Stéphane Vigouroux, Mauricette Michallet, Raphaël Porcher, et al.
Drugs
|
April 27, 2016
Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma
Philippe Moreau, Niels W C J van de Donk, Jesus San Miguel, et al.
Journal of Thrombosis and Haemostasis : JTH
|
June 16, 2025
Thromboembolism in transplant-ineligible multiple myeloma patients on triplet/quadruplet therapy: a post hoc analysis of BENEFIT trial
Emilie Chalayer, Corinne Frere, Elisabeth Daguenet, et al.
American Journal of Hematology
|
December 28, 2020
Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma
Jonathan L Kaufman, Cristina Gasparetto, Fredrik H Schjesvold, et al.
Blood
|
November 25, 2010
Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial
Philippe Moreau, Michel Attal, Brigitte Pégourié, et al.
British Journal of Haematology
|
January 28, 2009
Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline
Paul G Richardson, Pieter Sonneveld, Michael W Schuster, et al.
American Journal of Hematology
|
January 22, 2013
Efficacy of lenalidomide in POEMS syndrome: a retrospective study of 20 patients
Bruno Royer, Lavinia Merlusca, Julie Abraham, et al.
Blood Advances
|
March 27, 2026
FDG-PET Medullary Total Tumor Volume Highlights High-Risk Newly Diagnosed Multiple Myeloma Patients in CASSIOPEIA Trial
Jamet Bastien, Shamimeh Ahrari, Sonja Zweegman, et al.
The Oncologist
|
January 21, 2010
Current multiple myeloma treatment strategies with novel agents: a European perspective
Heinz Ludwig, Meral Beksac, Joan Bladé, et al.
Page
of 26
Search research articles
Search
Showing results (151-160 of 257) with videos related to
Sort By:
Page
of 26
Blood
|
February 27, 2026
Isatuximab, bortezomib, lenalidomide, dexamethasone for multiple myeloma: dynamics of MRD-negativity in the IMROZ study
Robert Z Orlowski, Meletios A Dimopoulos, Xavier Leleu, et al.
Haematologica
|
May 10, 2007
Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC)
Stéphane Vigouroux, Mauricette Michallet, Raphaël Porcher, et al.
Drugs
|
April 27, 2016
Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma
Philippe Moreau, Niels W C J van de Donk, Jesus San Miguel, et al.
Journal of Thrombosis and Haemostasis : JTH
|
June 16, 2025
Thromboembolism in transplant-ineligible multiple myeloma patients on triplet/quadruplet therapy: a post hoc analysis of BENEFIT trial
Emilie Chalayer, Corinne Frere, Elisabeth Daguenet, et al.
American Journal of Hematology
|
December 28, 2020
Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma
Jonathan L Kaufman, Cristina Gasparetto, Fredrik H Schjesvold, et al.
Blood
|
November 25, 2010
Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial
Philippe Moreau, Michel Attal, Brigitte Pégourié, et al.
British Journal of Haematology
|
January 28, 2009
Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline
Paul G Richardson, Pieter Sonneveld, Michael W Schuster, et al.
American Journal of Hematology
|
January 22, 2013
Efficacy of lenalidomide in POEMS syndrome: a retrospective study of 20 patients
Bruno Royer, Lavinia Merlusca, Julie Abraham, et al.
Blood Advances
|
March 27, 2026
FDG-PET Medullary Total Tumor Volume Highlights High-Risk Newly Diagnosed Multiple Myeloma Patients in CASSIOPEIA Trial
Jamet Bastien, Shamimeh Ahrari, Sonja Zweegman, et al.
The Oncologist
|
January 21, 2010
Current multiple myeloma treatment strategies with novel agents: a European perspective
Heinz Ludwig, Meral Beksac, Joan Bladé, et al.
Page
of 26